Glucagon (Gcg) is a peptide hormone, made by alpha cells of the pancreas. When blood glucose level is too low, glucagon-secreting alpha cells produce glucagon and release it into the bloodstream. Glucagon acts primarily on the liver, promoting the conversion of liver glycogen into glucose and the release of glucose into the bloodstream, known as glycogenolysis. It also facilitates gluconeogenesis, the production of glucose from amino acid molecules. Besides, it reduces glucose consumption by the liver as much as possible to ensure that more glucose flows into the blood pressure to keep blood sugar stable. In all, glucagon counteracts the effect of insulin on blood sugar, thus making blood glucose level in a narrow range.
The glucagon signaling pathway is a process of a series of elevated blood glucose enzymatic reactions triggered by the binding of glucagon that produced by pancreatic islets alpha cells to the glucagon receptor on the surface of liver cells.
Glucagon signaling pathway mainly assists glucagon to exert its role of raising blood glucose to sustain blood glucose homeostasis in the body and synergizes with insulin. In other words, the glucagon signaling pathway can prompt the catabolism of glucose, which is opposite to the role of the insulin signaling pathway.
The glucagon receptor (GcgR) is a member of the family B receptors within the G protein-coupled superfamily of seven transmembrane-spanning receptors. Glucagon receptors primarily distribute on the surface of liver and kidney cells. When blood glucose levels are low, pancreatic alpha cells secrete glucagon. And then, glucagon binds to glucagon receptors on the target organ, which induces a conformational change in the receptors, resulting in activation of the G proteins conjugated to the receptors, mainly Gs and Gq.
Activated Gs, in turn, activates adenylate cyclase, which catalyzes the production of cyclic adenosine monophosphate (cAMP) by ATP. The generated cAMP acts as a second messenger to activate the protein kinase A (PKA) pathway. In this pathway, elevated cAMP-activated PKA, in turn, activates glycogen phosphorylation kinase, which phosphorylates glycogen phosphorylase into an active alpha form that initiates the breakdown of hepatic glycogen, also known as glycogenolysis. cAMP can also phosphorylate glycogen synthase by PKA, inactivating glycogen synthase, thereby inhibiting glycogen synthesis. Besides, CAMP can also activate lipoprotein kinase via PKA to promote fat hydrolysis. The glycerin and fatty acid content in the plasma rises, and as a result, the gluconeogenesis is enhanced.
Upon the activation of Gq, the phospholipase c-inositol triphosphate channel is activated, resulting in intracellular Ca2+ release. Together with PKA, Ca2+ activates ERK1/2 protein, and ERK1/2 phosphorylation activates CREB. CREB is activated by ERK and binds to PGC-1 promoter to enhance PGC-1 expression. PGC-1 can up-regulate G-6-Pase and the transcription level of PEPCK, thereby increasing glucose.
Glucagon also stimulates beta-oxidation of liver mitochondria, which provides energy for glucose production.
DysfunctionGenetic variation and functional change of the protein molecules involved in the glucagon signaling pathway, as well as metabolic factors, cause abnormal signal transduction, which triggers hyperglycemia. So these abnormalities are also targets of drug therapy for hyperglycemia and related diseases.
Studies have confirmed that disruption of the glucagon signal leads to hyperglucoseemia and alpha-cell proliferation. Abnormal high-level secretion in patients with type II diabetes may be due not only to dysregulation of glucose levels and "missing" in islets, but may also reflect impaired glucagon signaling in the liver.
It has been reported that some patients with glucagonoma have very low amino acid levels, suggesting that pathological glucagon levels may cause liver inhalation of amino acids to be converted to urea. And the conversion may lead to severe hypoamino acidemia. It is well known that glucagon is a powerful regulator of amino acid production of liver urea.
Commonly, obese patients have dysfunction both in islet alpha and beta cells, resulting in excessive secretion of glucagon, impaired insulin secretion, thus triggering severe disorder of blood glucose metabolism in the body. Therefore, having a deep understanding of the glucagon signaling pathway is very helpful to research therapy for obesity.
|ACACA||ACACA Antibody||ACACA Protein||ACACA cDNA||ACACA ELISA Kit|
|ACACB||ACACB Antibody||ACACB Protein||ACACB cDNA||ACACB ELISA Kit|
|ADCY2||ADCY2 Antibody||ADCY2 Protein||ADCY2 cDNA||ADCY2 ELISA Kit|
|AKT1||AKT1 Antibody||AKT1 Protein||AKT1 cDNA||AKT1 ELISA Kit|
|AKT2||AKT2 Antibody||AKT2 Protein||AKT2 cDNA||AKT2 ELISA Kit|
|AKT3||AKT3 Antibody||AKT3 Protein||AKT3 cDNA||AKT3 ELISA Kit|
|ATF2||ATF2 Antibody||ATF2 Protein||ATF2 cDNA||ATF2 ELISA Kit|
|ATF4||ATF4 Antibody||ATF4 Protein||ATF4 cDNA||ATF4 ELISA Kit|
|CALML3||CALML3 Antibody||CALML3 Protein||CALML3 cDNA||CALML3 ELISA Kit|
|CALML4||CALML4 Antibody||CALML4 Protein||CALML4 cDNA||CALML4 ELISA Kit|
|CALML5||CALML5 Antibody||CALML5 Protein||CALML5 cDNA||CALML5 ELISA Kit|
|CALML6||CALML6 Antibody||CALML6 Protein||CALML6 cDNA||CALML6 ELISA Kit|
|CAMK2A||CAMK2A Antibody||CAMK2A Protein||CAMK2A cDNA||CAMK2A ELISA Kit|
|CAMK2B||CAMK2B Antibody||CAMK2B Protein||CAMK2B cDNA||CAMK2B ELISA Kit|
|CAMK2D||CAMK2D Antibody||CAMK2D Protein||CAMK2D cDNA||CAMK2D ELISA Kit|
|CAMK2G||CAMK2G Antibody||CAMK2G Protein||CAMK2G cDNA||CAMK2G ELISA Kit|
|CPT1A||CPT1A Antibody||CPT1A Protein||CPT1A cDNA||CPT1A ELISA Kit|
|CPT1B||CPT1B Antibody||CPT1B Protein||CPT1B cDNA||CPT1B ELISA Kit|
|CPT1C||CPT1C Antibody||CPT1C Protein||CPT1C cDNA||CPT1C ELISA Kit|
|CREB1||CREB1 Antibody||CREB1 Protein||CREB1 cDNA||CREB1 ELISA Kit|